🔗 Share this article World Health Organization Issues Alert Over Acute Shortage of Weight-Loss Injections Under one in 10 patients that would benefit from GLP-1 drugs like Wegovy are able to get them, warns the WHO as it publishes its inaugural guidance on the medications. With more than one billion individuals worldwide now obese, it is calling for increased and just access to this class of drugs. Per estimates, in excess of 2,000,000,000 could be obese by 2030 without intervention. "The latest guidelines affirms that obesity is a long-term condition that can be addressed with comprehensive and lifelong care," stated WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, limited production capacity, and distribution challenges are key obstacles to broad availability to the jabs that can help people shift considerable body mass, explains the organization. Skinny Jab Shortage Even under the current best projected outlook, the supply of GLP-1 therapies could only cover approximately 100 million people – under 10% of eligible patients, as stated by the health organization. The recommendation calls on governments and firms to widen availability, via strategies like licensing agreements. A patent on the active ingredient – the main component of the drug Wegovy – is scheduled to end in multiple countries in 2026. How Obesity Drugs Operate These medications imitate a biological compound to delay gastric emptying, curb appetite and increase the sense of being full so users reduce food intake. Individuals commonly begin shedding pounds after several weeks of commencing the weekly injections. Evidence points to people may see weight return within a year of discontinuing the drug, when their usual hunger return. To be carrying excess weight increases your likelihood for developing diseases, like type 2 diabetes, heart disease, stroke, and certain cancers. Excess weight concerns individuals in countries worldwide and was linked to 3.7 million deaths worldwide in 2024, according to the health agency.
Under one in 10 patients that would benefit from GLP-1 drugs like Wegovy are able to get them, warns the WHO as it publishes its inaugural guidance on the medications. With more than one billion individuals worldwide now obese, it is calling for increased and just access to this class of drugs. Per estimates, in excess of 2,000,000,000 could be obese by 2030 without intervention. "The latest guidelines affirms that obesity is a long-term condition that can be addressed with comprehensive and lifelong care," stated WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, limited production capacity, and distribution challenges are key obstacles to broad availability to the jabs that can help people shift considerable body mass, explains the organization. Skinny Jab Shortage Even under the current best projected outlook, the supply of GLP-1 therapies could only cover approximately 100 million people – under 10% of eligible patients, as stated by the health organization. The recommendation calls on governments and firms to widen availability, via strategies like licensing agreements. A patent on the active ingredient – the main component of the drug Wegovy – is scheduled to end in multiple countries in 2026. How Obesity Drugs Operate These medications imitate a biological compound to delay gastric emptying, curb appetite and increase the sense of being full so users reduce food intake. Individuals commonly begin shedding pounds after several weeks of commencing the weekly injections. Evidence points to people may see weight return within a year of discontinuing the drug, when their usual hunger return. To be carrying excess weight increases your likelihood for developing diseases, like type 2 diabetes, heart disease, stroke, and certain cancers. Excess weight concerns individuals in countries worldwide and was linked to 3.7 million deaths worldwide in 2024, according to the health agency.